News releases | Absci Corp

Year

10 Jan / 25

Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery

Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:

08 Jan / 25

Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery

$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug

06 Jan / 25

Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health

Collaboration leverages Absci’s leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications VANCOUVER, Wash. and BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug

02 Jan / 25

Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.